- Home
- ALLO vs OCFT Comparison
ALLO vs OCFT Comparison
Compare ALLO & OCFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- OCFT
- Stock Information
- Founded
- ALLO 2017
- OCFT 2015
- Country
- ALLO United States
- OCFT China
- Employees
- ALLO N/A
- OCFT N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- OCFT Computer Software: Programming Data Processing
- Sector
- ALLO Health Care
- OCFT Technology
- Exchange
- ALLO Nasdaq
- OCFT Nasdaq
- Market Cap
- ALLO 363.1M
- OCFT 290.5M
- IPO Year
- ALLO 2018
- OCFT 2019
- Fundamental
- Price
- ALLO $1.40
- OCFT $7.42
- Analyst Decision
- ALLO Strong Buy
- OCFT
- Analyst Count
- ALLO 9
- OCFT 0
- Target Price
- ALLO $8.44
- OCFT N/A
- AVG Volume (30 Days)
- ALLO 3.5M
- OCFT 57.7K
- Earning Date
- ALLO 08-06-2025
- OCFT 08-15-2025
- Dividend Yield
- ALLO N/A
- OCFT N/A
- EPS Growth
- ALLO N/A
- OCFT N/A
- EPS
- ALLO N/A
- OCFT N/A
- Revenue
- ALLO N/A
- OCFT $260,815,958.00
- Revenue This Year
- ALLO N/A
- OCFT N/A
- Revenue Next Year
- ALLO $199.63
- OCFT $6.37
- P/E Ratio
- ALLO N/A
- OCFT N/A
- Revenue Growth
- ALLO N/A
- OCFT N/A
- 52 Week Low
- ALLO $0.86
- OCFT $0.87
- 52 Week High
- ALLO $3.78
- OCFT $7.64
- Technical
- Relative Strength Index (RSI)
- ALLO 54.41
- OCFT 55.02
- Support Level
- ALLO $1.21
- OCFT $7.32
- Resistance Level
- ALLO $1.31
- OCFT $7.57
- Average True Range (ATR)
- ALLO 0.11
- OCFT 0.15
- MACD
- ALLO 0.02
- OCFT -0.02
- Stochastic Oscillator
- ALLO 40.82
- OCFT 30.77
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
About OCFT OneConnect Financial Technology Co. Ltd.
OneConnect Financial Technology Co Ltd is a technology-as-a-service provider for the financial services industry. It integrates extensive expertise in the industry with market technology to provide technology applications and technology-enabled business services to financial institutions. The integrated solutions and platforms it provides include digital banking solutions, digital insurance solutions, and the Gamma Platform, a technology infrastructure platform for financial institutions. Geographically, the company generates substantially all of its revenue from its business in the People's Republic of China (PRC).